Inhalational Anthrax

• FDA approval · 2021-06-02
  FDA Approved: RAXIBACUMAB — Supplemental Application (Emergent Manufacturing Operations Baltimore LLC)

  FDA approved a supplemental application for manufacturing operations of RAXIBACUMAB (raxibacumab) by Emergent Manufacturing Operations Balti…

• FDA approval · 2019-11-29
  FDA Approved: ANTHIM — Supplemental Application (Elusys Therapeutics, Inc.)

  FDA approved a supplemental application for ANTHIM (obiltoxaximab) from Elusys Therapeutics, Inc.

• FDA approval · 2018-01-11
  FDA Approved: RAXIBACUMAB — Supplemental Application (Emergent Manufacturing Operations Baltimore LLC)

  The FDA approved a supplemental application to support manufacturing operations for the biologic Raxibacumab, submitted by Emergent Manufact…

• FDA approval · 2016-10-20
  FDA Approved: ANTHIM — Supplemental Application (Elusys Therapeutics, Inc.)

  FDA approved a supplemental application for ANTHIM (obiltoxaximab) from Elusys Therapeutics, Inc.

• FDA approval · 2016-03-18
  FDA Approved: ANTHIM — Original Application (Elusys Therapeutics, Inc.)

  FDA approved ANTHIM (obiltoxaximab) from Elusys Therapeutics as an original application for the treatment of inhalational anthrax in combina…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2012-12-14
  FDA Approved: RAXIBACUMAB — Original Application (Emergent Manufacturing Operations Baltimore LLC)

  FDA approved raxibacumab under an original biologics license application for treatment of inhalational anthrax when used with antibiotics. T…